CTOs on the Move

Shared Health Services

www.sharedhealthservices.com

 
Shared Health Services is a wound care management company that contracts with hospitals to help them open and manage successful outpatient wound care and hyperbaric centers. The mission of our Wound Care Centers is to heal chronic wounds, improve patient outcomes, help prevent limb loss and provide a profitable service for our contracted hospitals.
  • Number of Employees: 25-100
  • Annual Revenue: $10-50 Million

Executives

Name Title Contact Details

Similar Companies

Loretto

Loretto is a Syracuse, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Destination Pet

Welcome to your destination. Our mission is simple: to provide the best for your pet.

Ontario Long Term Care Association

Ontario Long Term Care Association is a Markham, ON-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Exeter House

Exeter House is a Seattle, WA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Mela Sciences

At MELA Sciences, we design and develop innovative software-driven medical technologies for physician clinical use during the detection of skin cancers at the most curable and cost-effective stages. Our mission is to develop breakthrough medical technologies to improve skin cancer detection and achieve better outcomes for all. We envision a world in which our pioneering innovations will change the way patients think about skin cancer, while providing dermatologists and clinicians with new, effective, non-invasive tools for the earliest detection possible. MELA Sciences conducted the largest, positive prospective study ever done on the melanoma disease, and is the first and only medical technology company to receive both FDA Pre-Market Approval (PMA) for the U.S. and CE Marking certification for the European Union for a device of this nature. The company’s flagship product, MelaFind®, is intended to provide dermatologists with software-driven image analysis of clinically atypical pigmented skin lesions when they choose to obtain additional information to help decide whether to biopsy or not. The FDA has approved MELA Sciences’ MelaFind® Pre-Market Approval application for use in the United States and MELA Sciences has also been granted CE Mark approval for sale of MelaFind® in the European Union.